Replimune Group, Inc.

Replimune ended fiscal 2025 with cash and cash equivalents of $483.8 million, up from $420.7 million at fiscal 2024 year-end. Research and development expense was $54.0 million in the fiscal fourth quarter and $189.4 million for the fiscal year, versus $42.6 million and $175.0 million a year earlier. Selling, general and administrative expense was $25.4 million in the quarter and $72.2 million for the year, versus $16.2 million and $59.8 million last year. Net loss was $74.1 million in the quarter and $247.3 million for the year, compared with $55.1 million and $215.8 million in the prior-year periods. Management said existing cash, cash equivalents and short-term investments should fund operations into the fourth quarter of 2026, including scale-up for potential RP1 commercialization. No revenue guidance was given; Emily Hill said they will provide launch metrics first and hold off on revenue guidance until further into the launch.

Sushil Patel framed the year as a major inflection point, emphasizing regulatory, clinical, and commercial progress ahead of a potential first approval and launch of RP1. He highlighted breakthrough therapy designation, priority review, the PDUFA date, and the ongoing confirmatory IGNYTE 3 study, which has overall survival as its primary endpoint. His tone was confident and launch-focused, repeatedly stressing that RP1 could be positioned as an important option for advanced melanoma patients who have progressed on anti-PD-1 therapy. He also pointed to pipeline potential beyond melanoma through RPX and future studies in other tumors.

Emily Hill focused on liquidity, burn, and launch readiness. She said the company ended the fiscal year with $483.8 million in cash and cash equivalents, up from $420.7 million a year earlier, and expects current resources to fund operations into Q4 2026, excluding any potential revenue. She quantified spending increases tied to commercial preparation: R&D rose to $54.0 million in the quarter and $189.4 million for the year, while SG&A was $25.4 million and $72.2 million, respectively. She also said the company completed FDA inspections and does not see those formal inspection findings as a bottleneck for the July 22 PDUFA.

Analysts focused on launch trajectory, FDA/regulatory risk, label breadth, IGNYTE 3 enrollment, manufacturing resilience, and the timing of revenue guidance. Management said FDA interactions have been consistent, the late-cycle meeting and inspections are done, and they see no impediments to the July 22 PDUFA. On the clinical side, Patel said IGNYTE showed roughly one-third of patients achieved durable responses, median duration of response was more than 20 months, PFS was around 4 months, and more than about 55% of patients were alive at 3 years; he argued that the label should reflect the broad real-world population studied. On commercialization, management said about 350 key accounts cover roughly half the melanoma population, about 150 should have injection experience or training by launch, and over 90% of physicians they spoke with are willing to use RP1 routinely upon approval.